Welcome, Mike Doustdar - our 6th CEO! With 30+ years of company experience, Mike brings a track record of growth and high performing teams within Novo Nordisk. "I'm a forever-optimist when it comes to Novo Nordisk. I see multiple growth drivers and a company that can accelerate its positive impact on the world." Time to write our next chapter.
Novo Nordisk
Produktion af lægemidler
We’re here to champion long-term health. Get updates on innovation and inspiring stories 💙 #UnordinaryDrivesChange
Om os
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Karen J. Kolin
Clinical Research Relationship Specialist
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Sören Meelby
Digital Healthcare Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
Our results from the first six months of 2025 are out. Learn more in the video below or here 👉 https://lnkd.in/gu4MH2U #UnordinaryDrivesChange
-
34 years in Novo Nordisk is coming to an end for our CEO Lars Fruergaard Jørgensen. Thank you, Lars. From all of us 💙
-
Does urban living impact your long-term health? Almost a hundred years ago, our founders, Marie and August Krogh, were researching and talking about the ways urban living can impact public health. Find out how their vision lives on today in our Cities for Better Health programme: https://lnkd.in/e9_dnZX #UnordinaryDrivesChange
-
How do you keep life-saving insulin cold if you don’t have a fridge? Or any power? We’ve been working to make insulin accessible to people who… ☀️ …live in hot places 🧊 …don’t have regular access to a fridge ⚡ …don’t have reliable power Learn more about our commitment to making life-saving medications more accessible: https://lnkd.in/dAtmDGc3 #UnordinaryDrivesChange
-
We’re excited to announce that Maziar Mike Doustdar has been appointed as our president and CEO. Read on to learn more about Mike and his 33-year career at Novo Nordisk 👉 https://lnkd.in/dJC4XAzh
-
-
Is weight loss only about counting calories? Let’s set the record straight and debunk the most common misconceptions about obesity. Comment below to tell us what you’d like us to debunk next 👇 #UnordinaryDrivesChange
-
Is weight loss predominantly about appearance? Think again. For people living with obesity, losing just 5–10% of body weight can lead to major health wins, like better heart health, a lower risk of type 2 diabetes, and even reversing early liver disease (MASH). We’re on a mission to drive long-term health, and would like to hear from you 👇 #UnordinaryDrivesChange
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
-
For people with obesity, weight loss may help change appearances but do you know about the long-term benefits? Our colleague Rochelle is here to set the record straight. From reducing the risk of type 2 diabetes by 58% to even reversing liver disease. Learn about the science of obesity: https://lnkd.in/eCyWpsQ #UnordinaryDrivesChange
-
40 years ago, we wrote a new chapter in insulin delivery by introducing the first reusable injection pen to patients. Since then, we’ve continued to innovate to support healthier lives for people living with serious chronic diseases – and today, injection pens are used for treatments beyond diabetes. #UnordinaryDrivesChange
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
Tilsvarende sider
Finansiering
Novo Nordisk
1 runde i alt
Læs mere på crunchbase
Seneste runde
Post IPO-egenkapital
Eksternt Crunchbase-link til seneste finansieringsrunde
22.000.000,00 US$